Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
Total Valuation
PMV Pharmaceuticals has a market cap or net worth of $61.82M. The enterprise value is $1.71B.
Market Cap$61.82M
Enterprise Value$1.71B
Share Statistics
PMV Pharmaceuticals has 51,952,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,952,680
Owned by Insiders3.02%
Owned by Institutions54.77%
Financial Efficiency
PMV Pharmaceuticals’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -37.83%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-37.83%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count47
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PMV Pharmaceuticals is -1.33. PMV Pharmaceuticals’s PEG ratio is -11.88.
PE Ratio-1.33
PS Ratio0.00
PB Ratio-22.89
Price to Fair Value0.44
Price to FCF-72.74
Price to Operating Cash Flow-73.10
PEG Ratio-11.88
Income Statement
In the last 12 months, PMV Pharmaceuticals had revenue of 0.00 and earned -58.71M in profits. Earnings per share was -1.14.
Revenue0.00
Gross Profit0.00
Operating Income-85.45M
Pretax Income-74.81M
Net Income-58.71M
EBITDA-73.67M
Earnings Per Share (EPS)-1.14
Cash Flow
In the last 12 months, operating cash flow was -53.36M and capital expenditures -65.00K, giving a free cash flow of -53.43M billion.
Operating Cash Flow-53.36M
Free Cash Flow-53.43M
Free Cash Flow per Share-1.03
Dividends & Yields
PMV Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-34.73%
50-Day Moving Average0.96
200-Day Moving Average1.35
Relative Strength Index (RSI)62.82
Average Volume (3m)321.23K
Important Dates
PMV Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 9, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
PMV Pharmaceuticals as a current ratio of 12.22, with Debt / Equity ratio of -239.71%
Current Ratio12.22
Quick Ratio12.22
Debt to Market Cap<0.01
Net Debt to EBITDA0.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PMV Pharmaceuticals has paid -16.10M in taxes.
Income Tax-16.10M
Effective Tax Rate0.22
Enterprise Valuation
PMV Pharmaceuticals EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.74.
EV to Sales0.00
EV to EBITDA-0.52
EV to Free Cash Flow-0.74
EV to Operating Cash Flow-0.74
Balance Sheet
PMV Pharmaceuticals has $160.39M in cash and marketable securities with $1.11M in debt, giving a net cash position of -$159.28M billion.
Cash & Marketable Securities$160.39M
Total Debt$1.11M
Net Cash-$159.28M
Net Cash Per Share-$3.07
Tangible Book Value Per Share$3.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PMV Pharmaceuticals is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside342.48% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast21.33%